September 18, 2012
Astellas Pharma announced on September 14 that it has launched XTANDI (enzalutamide), an oral androgen receptor inhibitor, in the US. XTANDI is indicated for the treatment of metastatic castration-resistant prostate cancer in patients who have previously received docetaxel. It was...read more